Immunotherapy, as an emerging treatment strategy for advanced PCa, its therapeutic agents mainly include Sipuleucel-T, an autologous vaccine targeting PAP, and ipilimumab, which targets CTLA-4. Here, CTLA4 is linked to posterior cortical atrophy.